Literature DB >> 21232524

Pathogenesis of nonmelanoma skin cancers in organ transplant recipients.

Mohammad Athar1, Stephanie B Walsh, Levy Kopelovich, Craig A Elmets.   

Abstract

Nonmelanoma skin cancer (NMSC) is the most common human cancer, with an incidence of more than 1.2 million per year in the USA. The risk for the development of NMSCs increases by approximately 10-250 fold in chronically immune suppressed organ transplant recipients (OTRs). Solar UVB is the most common etiologic factor in the development of this neoplasm, both in immune competent and immune suppressed populations. This review provides a description of NMSC in OTRs. It also provides an account of the various immunologic and non-immune-dependent mechanisms involved in the pathogenesis and progression of NMSCs in OTRs. Finally, this review addresses possible strategies for the prevention of this cancer, particularly focusing on the aspects that may be incorporated to prevent negative effects of chemopreventive chemicals on graft survival.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21232524      PMCID: PMC3063391          DOI: 10.1016/j.abb.2011.01.004

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  52 in total

1.  The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence.

Authors:  K J Purdie; J Pennington; C M Proby; S Khalaf; E M de Villiers; I M Leigh; A Storey
Journal:  EMBO J       Date:  1999-10-01       Impact factor: 11.598

2.  Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment.

Authors:  Daniel G Maluf; Valeria R Mas; Kellie J Archer; Kenneth Yanek; Anne King; Andrea Ferreira-Gonzalez; Robert A Fisher; Marc Posner
Journal:  Transplantation       Date:  2005-12-27       Impact factor: 4.939

3.  Excess risk of cancer in renal transplant patients.

Authors:  Michèle Kessler; Nicolas Jay; Rachel Molle; Francis Guillemin
Journal:  Transpl Int       Date:  2006-11       Impact factor: 3.782

4.  Anti-rejection drug treatment increases basal cell carcinoma burden in Ptch1+/- mice.

Authors:  Annika Vogt; Jennifer Hebert; Jimmy Hwang; Ying Lu; Ervin H Epstein
Journal:  J Invest Dermatol       Date:  2005-01       Impact factor: 8.551

5.  Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease.

Authors:  Clark C Otley; Wida S Cherikh; Stuart J Salasche; Maureen A McBride; Leslie J Christenson; H Myron Kauffman
Journal:  J Am Acad Dermatol       Date:  2005-09-22       Impact factor: 11.527

6.  The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths.

Authors:  Kilian Perrem; Ailish Lynch; Maura Conneely; Henrik Wahlberg; Gillian Murphy; Mary Leader; Elaine Kay
Journal:  Hum Pathol       Date:  2006-11-28       Impact factor: 3.466

Review 7.  Oxidative stress in the pathogenesis of skin disease.

Authors:  David R Bickers; Mohammad Athar
Journal:  J Invest Dermatol       Date:  2006-12       Impact factor: 8.551

Review 8.  Systemic strategies for chemoprevention of skin cancers in transplant recipients.

Authors:  Bradley T Kovach; Hunter H Sams; Thomas Stasko
Journal:  Clin Transplant       Date:  2005-12       Impact factor: 2.863

9.  Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens.

Authors:  P Jensen; S Hansen; B Møller; T Leivestad; P Pfeffer; O Geiran; P Fauchald; S Simonsen
Journal:  J Am Acad Dermatol       Date:  1999-02       Impact factor: 11.527

10.  Azathioprine and UVA light generate mutagenic oxidative DNA damage.

Authors:  Peter O'Donovan; Conal M Perrett; Xiaohong Zhang; Beatriz Montaner; Yao-Zhong Xu; Catherine A Harwood; Jane M McGregor; Susan L Walker; Fumio Hanaoka; Peter Karran
Journal:  Science       Date:  2005-09-16       Impact factor: 47.728

View more
  20 in total

1.  Nitric oxide donor exisulind is an effective inhibitor of murine photocarcinogenesis.

Authors:  Tripti Singh; Sandeep C Chaudhary; Puneet Kapur; Zhiping Weng; Craig A Elmets; Levy Kopelovich; Mohammad Athar
Journal:  Photochem Photobiol       Date:  2012-02-24       Impact factor: 3.421

2.  Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention.

Authors:  Mohammad Athar; Levy Kopelovich
Journal:  Cancer Prev Res (Phila)       Date:  2011-07

3.  Combined inhibition of p38 and Akt signaling pathways abrogates cyclosporine A-mediated pathogenesis of aggressive skin SCCs.

Authors:  Aadithya Arumugam; Stephanie B Walsh; Jianmin Xu; Farrukh Afaq; Craig A Elmets; Mohammad Athar
Journal:  Biochem Biophys Res Commun       Date:  2012-07-20       Impact factor: 3.575

4.  Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway.

Authors:  Jianmin Xu; Stephanie B Walsh; Zoe M Verney; Levy Kopelovich; Craig A Elmets; Mohammad Athar
Journal:  Biochem Biophys Res Commun       Date:  2011-02-17       Impact factor: 3.575

5.  Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells.

Authors:  Karin A Vineretsky; Margaret R Karagas; Brock C Christensen; Jacquelyn K Kuriger-Laber; Ann E Perry; Craig A Storm; Heather H Nelson
Journal:  Cancer Res       Date:  2016-01-07       Impact factor: 12.701

Review 6.  The Role of Classical and Novel Forms of Vitamin D in the Pathogenesis and Progression of Nonmelanoma Skin Cancers.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Zorica Janjetovic; Tae-Kang Kim; Radomir M Slominski; Robert C Tuckey; Rebecca S Mason; Anton M Jetten; Purushotham Guroji; Jörg Reichrath; Craig Elmets; Mohammad Athar
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 7.  Molecular signaling cascades involved in nonmelanoma skin carcinogenesis.

Authors:  Robert P Feehan; Lisa M Shantz
Journal:  Biochem J       Date:  2016-10-01       Impact factor: 3.857

8.  Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma.

Authors:  Melody Abikhair Burgo; Nazanin Roudiani; Jie Chen; Alexis L Santana; Nicole Doudican; Charlotte Proby; Diane Felsen; John A Carucci
Journal:  JCI Insight       Date:  2018-09-06

9.  Exploiting the origins of Ras mediated squamous cell carcinoma to develop novel therapeutic interventions.

Authors:  Andrew C White; William E Lowry
Journal:  Small GTPases       Date:  2011-11-01

10.  5'-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma.

Authors:  Ritesh Kumar Srivastava; Jasim Khan; Aadithya Arumugam; Suhail Muzaffar; Purushotham Guroji; Marina S Gorbatyuk; Craig A Elmets; Andrzej T Slominski; M Shahid Mukhtar; Mohammad Athar
Journal:  J Invest Dermatol       Date:  2020-09-21       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.